116 related articles for article (PubMed ID: 16102455)
1. Long-term calcineurin inhibitor "holiday" using daclizumab in a heart transplant patient with acute renal dysfunction.
Potter B; Giannetti N; Cecere R; Cantarovich M
J Heart Lung Transplant; 2005 Aug; 24(8):1126-8. PubMed ID: 16102455
[No Abstract] [Full Text] [Related]
2. Repeated daclizumab administration to delay the introduction of calcineurin inhibitors in heart transplant patients with postoperative renal dysfunction.
Sánchez Lázaro IJ; Almenar Bonet L; Martínez Dolz L; Buendía Fuentes F; Navarro Manchón J; Agüero Ramón-Llin J; Vicente Sánchez JL; Salvador Sanz A
Rev Esp Cardiol; 2011 Mar; 64(3):237-9. PubMed ID: 21310520
[TBL] [Abstract][Full Text] [Related]
3. Rituximab therapy in early recurrent focal segmental sclerosis after renal transplantation.
Apeland T; Hartmann A
Nephrol Dial Transplant; 2008 Jun; 23(6):2091-4. PubMed ID: 18319357
[No Abstract] [Full Text] [Related]
4. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
[TBL] [Abstract][Full Text] [Related]
5. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
Cuppoletti A; Perez-Villa F; Vallejos I; Roig E
Transplant Proc; 2005 Nov; 37(9):4036-8. PubMed ID: 16386620
[TBL] [Abstract][Full Text] [Related]
6. Following-up of a four-dose daclizumab induction therapy without calcineurin inhibitors in a liver transplantation recipient with severe renal dysfunction: a case report.
Zhang Y; Wen T; Yan L; Chen Z; Li B; Zeng Y
Transplant Proc; 2008 Dec; 40(10):3819-20. PubMed ID: 19100502
[TBL] [Abstract][Full Text] [Related]
7. [The role of some selected risk factors in the development of the nephrotoxicity of immunosuppressive medications used after the heart transplantation in children and young adults].
Hyla-Klekot L; Kucharska G
Przegl Lek; 2006; 63 Suppl 3():40-3. PubMed ID: 16898485
[TBL] [Abstract][Full Text] [Related]
8. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
Demirjian S; Stephany B; Abu Romeh IS; Boumitri M; Yamani MH; Poggio ED
Clin Transplant; 2009; 23(3):351-60. PubMed ID: 19208105
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
Potter BJ; Giannetti N; Edwardes MD; Cecere R; Cantarovich M
Clin Transplant; 2007; 21(3):305-8. PubMed ID: 17488377
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppression for heart transplantation: where are we now?
Kobashigawa JA; Patel JK
Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):203-12. PubMed ID: 16568129
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
12. Induction therapy with daclizumab in heart transplantation--how many doses?
Ortiz V; Almenar L; Martínez-Dolz L; Zorio E; Chamorro C; Moro J; Agüero J; Rueda J; Arnau MA; Salvador A
Transplant Proc; 2006 Oct; 38(8):2541-3. PubMed ID: 17097995
[TBL] [Abstract][Full Text] [Related]
13. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
[TBL] [Abstract][Full Text] [Related]
14. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
Bajjoka I; Hsaiky L; Brown K; Abouljoud M
Liver Transpl; 2008 Jan; 14(1):66-72. PubMed ID: 18161842
[TBL] [Abstract][Full Text] [Related]
15. Renal protective strategies in heart transplant patients.
Cantarovich M
Curr Opin Cardiol; 2007 Mar; 22(2):133-8. PubMed ID: 17284993
[TBL] [Abstract][Full Text] [Related]
16. Association of ANCA-positive vasculitis with thyroid disease.
Rothe HM; Siegmund J; Müller H; Wopperer J
Nephrol Dial Transplant; 2008 Jun; 23(6):2107; author reply 2107-8. PubMed ID: 18323519
[No Abstract] [Full Text] [Related]
17. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation.
Hunt J; Lerman M; Magee MJ; Dewey TM; Herbert M; Mack MJ
J Heart Lung Transplant; 2005 Nov; 24(11):1863-7. PubMed ID: 16297793
[TBL] [Abstract][Full Text] [Related]
18. Two-dose daclizumab induction in pediatric renal transplantation.
Jain A; Valentini RP; Gruber SA; West MS; Mattoo TK; Imam AA
Pediatr Transplant; 2009 Jun; 13(4):490-4. PubMed ID: 18992052
[TBL] [Abstract][Full Text] [Related]
19. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
González-Vílchez F; de Prada JA; Exposito V; García-Camarero T; Fernández-Friera L; Llano M; Ruano J; Martín-Durán R
J Heart Lung Transplant; 2008 Oct; 27(10):1135-41. PubMed ID: 18926406
[TBL] [Abstract][Full Text] [Related]
20. A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study.
Washburn WK; Teperman LW; Heffron TG; Douglas DD; Gay S; Katz E; Klintmalm GB
Liver Transpl; 2006 Apr; 12(4):585-91. PubMed ID: 16456831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
